Liquidia Technologies is a privately-held clinical stage company focused on advancing vaccines and therapeutics that leverage the PRINTtechnology for design and manufacture of engineered particles. The PRINTtechnology offers unprecedented control of particle size, shape and chemistry in a highly consistent and scalable manufacturing process. In addition to its own products, Liquidia licenses its PRINTparticle technology and its GMP manufacturing capabilities to support proprietary programs advanced by collaborators.
We are committed to advancing precisely engineered products that profoundly impacts the lives of patients.
Liquidia is proud of its cultural values and strives for excellence and innovation in everything that we do.
Liquidia was founded in 2004 on the discoveries of Professor Joseph DeSimone at UNC, Chapel Hill
We are located in Research Triangle Park, North Carolina.
For additional information, please visit www.liquidia.com
P.O. Box 110085
Research Triangle Park, NC 27709